

22 March 2012

AquaBounty Technologies, Inc.
(“AquaBounty” or “the Company”)

Result of General Meeting

Further to the announcement of 22 February 2012, the Board of AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces that at the General Meeting of shareholders held earlier today, all resolutions were duly passed.

The Company will proceed to complete the transaction to raise approximately £1.26 million (c.\$2.0 million) before expenses by means of a subscription of new Common Shares (the “Subscription Shares”) by certain existing shareholders of the Company. Admission to AIM and commencement of trading of the Subscription Shares is scheduled to occur on 26 March 2012. The Company expects that this funding will enable AquaBounty to continue its activities for at least the next 10 months.

Richard Clothier, Chairman of AquaBounty, commented: “We are very pleased that shareholders have continued to be supportive as we wait upon the USA Food and Drug Administration to complete the approval process for AquaAdvantage[®] Salmon. The Board remains hopeful that the Company will receive approval, and is prepared and ready to move quickly to the commercialization phase.”

For further information, please contact:

AquaBounty Technologies
David Frank, Chief Financial Officer

+1 781 899 7755

Nomura Code Securities
Giles Balleny

+44(0)20 7776 1200

Luther Pendragon
Harry Chathli, Claire Norbury

+44 (0)20 7618 9100